Showing results (1-10 of 22) with videos related to
Sort By:
Pageof 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2005
Role of genomic markers in colorectal cancer treatmentWendy L Allen, Patrick G JohnstonPharmacogenomics|September 7, 2005
Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancerWendy L Allen, Patrick G JohnstonBiochimica Et Biophysica Acta|September 16, 2006
Drug resistance, predictive markers and pharmacogenomics in colorectal cancerDaniel B Longley, Wendy L Allen, Patrick G JohnstonCurrent Opinion in Pharmacology|June 6, 2006
Predicting the outcome of chemotherapy for colorectal cancerWendy L Allen, Vicky M Coyle, Patrick G JohnstonNature Reviews. Clinical Oncology|February 16, 2011
Implementing prognostic and predictive biomarkers in CRC clinical trialsSandra Van Schaeybroeck, Wendy L Allen, Richard C Turkington, et al.Seminars in Oncology|June 13, 2003
The interaction of thymidylate synthase expression with p53-regulated signaling pathways in tumor cellsDaniel B Longley, Tariq Latif, John Boyer, et al.Molecular Cancer Therapeutics|September 3, 2009
Prostate-derived factor--a novel inhibitor of drug-induced cell death in colon cancer cellsIrina Proutski, Leanne Stevenson, Wendy L Allen, et al.Molecular Cancer Therapeutics|May 22, 2007
Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cellsKatherine M A Rogers, Michelle Thomas, Leeona Galligan, et al.Plos One|June 2, 2011
Calbindin 2 (CALB2) regulates 5-fluorouracil sensitivity in colorectal cancer by modulating the intrinsic apoptotic pathwayLeanne Stevenson, Wendy L Allen, Irina Proutski, et al.Cancer Research|March 3, 2006
Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancerJohn Boyer, Wendy L Allen, Estelle G McLean, et al.Pageof 3